📋 Tender Overview
Project Type
Coordinated Research Project
Project Code
F22077
CRP
2330
Approved Date
6 September 2023
Status
Active - Ongoing
Start Date
21 May 2024
Expected End Date
30 June 2029
Participating Countries
Italy
Description
IAEA continues to harness the CRP mechanism as a major platform for coordination of research and development activities on the production and quality control of radiopharmaceuticals and their application for non-communicable human diseases. This is an important part of the IAEA's remit to generate amd distribute knowledge involving atoms for peace for all Member States. In order to best optimise production and sustainable application of Tc-99m and related kits worldwide as well as define future activities to enhance and develop production capacities in Mmber States, the IAEA has recently held a number of meetings and networking activties on the subject . From those meetings, a major recommendation was put forward to plan and initiate an IAEA CRP for 2024-2028 on the development of novel target kits and molecules, and enhance their impact by strengthening mechanisms of knowledge transfer of the related radiopharmaceuticals (small molecules, peptides, antibodies, etc.), preclinical studies and health regulatory issues, etc. As an outcome of the CRP, the IAEA Member States should adopt the developed kit/molecule production and preclinical evaluation of selected Tc-99m radiopharmaceuticals with IAEA's assistance through published guidelines. Many IAEA Member States are potential users of these materials and would benefit from such a publication/guideline.
Objectives
The main objective of the Coordinated Research Project (CRP) is to transfer the knowledge acquired to produce a series of technetium-99m (99mTc) radiopharmaceuticals for imaging various biological substrates of relevant clinical interest using the most efficient methods of Tc-99m labelling. Several 99mTc radiopharmaceuticals will be produced for imaging the following biological substrates, as follows:
Specific objectives
Research and development on prostate specific membrane antigen (PSMA) receptors ligands
Research and development on peptides/small molecules targeting receptors expressed by cancerous lesions classified as poor-prognostic solid tumors (HCC, breast cancer).
Tumor microenvironment studies using newly developed ligands
To perform round robins comprised of labelling kit formulations previously developed for the preparation of 99mTc radiopharmaceuticals used in myocardial perfusion, bone imaging, tumor imaging, infection processes and sentinel lymph node detection (SLND)
To sort out suitable and efficient quality control procedures and pre-clinical assays for assessing the overall quality of 99mTc radiopharmaceuticals prepared during the CRP.
To enhance capacity-building for applying freeze-drying methods and technologies to the development of lyophilized kit formulations of 99mTc radiopharmaceuticals investigated dur
